Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Quisinostat |
| Synonyms | |
| Therapy Description |
Quisinostat (JNJ-26481585) is a second-generation HDAC inhibitor, which increases histone acetlyation, and may increase tumor cell apoptosis and inhibit tumor growth (PMID: 24038993, PMID: 19861438, PMID: 31784862). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Quisinostat | JNJ-26481585|JNJ-6481585 | HDAC Inhibitor 45 | Quisinostat (JNJ-26481585) is a second-generation HDAC inhibitor, which increases histone acetlyation, and may increase tumor cell apoptosis and inhibit tumor growth (PMID: 24038993, PMID: 19861438, PMID: 31784862). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06824662 | Phase I | Quisinostat | Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas | Recruiting | USA | 0 |
| NCT06932757 | Phase II | Quisinostat | Adjuvant Quisinostat in High-Risk Uveal Melanoma | Recruiting | USA | 0 |